On March 23, Boji Medical Technology Co.Ltd(300404) ( Boji Medical Technology Co.Ltd(300404) ) announced the equity incentive plan, which plans to grant 2.7 million stock options, accounting for 1.0326% of the total share capital of the company. According to the announcement, the incentive plan grants a total of 87 incentive objects, and the exercise price is 12.27 yuan / share.
Specifically, the stock options granted by the incentive plan are assessed from two dimensions: the company and the individual. At the company level, the assessment year corresponding to option exercise is three years from 2022 to 2024, and the year-on-year growth rate of operating revenue in each year is required to be no less than 25%, 50% and 80% respectively. Under the condition of meeting the performance assessment standards at the company level in each year, the actual exercise amount of the incentive object will also be distributed and calculated in combination with the individual comprehensive evaluation results.
It is noteworthy that the profitability of Boji Medical Technology Co.Ltd(300404) is gradually increasing, which helps to ensure the continuous and rapid growth of the company’s performance. According to the announcement, in the third quarter of 2021, the operating revenue of the company reached 940266 million yuan, a year-on-year increase of 40.47%; The net profit attributable to the parent company after deduction was 177487000 yuan, a year-on-year increase of 222.83%.
The company said that the implementation of the equity incentive plan will further improve the corporate governance structure, establish and improve the company’s incentive and restraint mechanism, ensure the smooth implementation of the company’s equity incentive plan, give full play to the role of equity incentive to the greatest extent, promote the common growth of the company and employees, and then ensure the realization of the company’s development strategy and business objectives. (CIS)
